期刊
THERAPEUTICS AND CLINICAL RISK MANAGEMENT
卷 13, 期 -, 页码 1363-1374出版社
DOVE MEDICAL PRESS LTD
DOI: 10.2147/TCRM.S141991
关键词
circulating tumor DNA; ctDNA; liquid biopsy; cancer monitoring; tumor heterogeneity; targeted therapies; biomarkers
Circulating cell-free DNA (cfDNA) released by tumor cells, termed ctDNA, closely reflects the heterogeneity of primary cancers and their metastases. As a noninvasive, real-time monitoring biomarker, ctDNA is a promising tool for detecting driver gene mutations, assessing tumor burden and acquired resistance, and early diagnosis. However, isolation and enrichment of cfDNA is a big challenge due to the high degree of DNA fragmentation and its relatively low abundance in the bloodstream. This review aims to provide insights into the recent technological advances in acquisition of optimal quality cfDNA, the use of preservatives, isolation methods, processing timelines, and detection techniques. It also describes clinical applications of ctDNA in cancer patient management.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据